SMT201600073B - Inibitori della mitosi per aumentare l'apoptosi in terapia - Google Patents

Inibitori della mitosi per aumentare l'apoptosi in terapia

Info

Publication number
SMT201600073B
SMT201600073B SM201600073T SM201600073T SMT201600073B SM T201600073 B SMT201600073 B SM T201600073B SM 201600073 T SM201600073 T SM 201600073T SM 201600073 T SM201600073 T SM 201600073T SM T201600073 B SMT201600073 B SM T201600073B
Authority
SM
San Marino
Prior art keywords
mythosis
inhibitors
therapy
increase apoptosis
apoptosis
Prior art date
Application number
SM201600073T
Other languages
English (en)
Inventor
Brian J Tunquist
Duncan H Walker
Richard Donald Woessner
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of SMT201600073B publication Critical patent/SMT201600073B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SM201600073T 2008-10-16 2016-03-14 Inibitori della mitosi per aumentare l'apoptosi in terapia SMT201600073B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10608608P 2008-10-16 2008-10-16
PCT/US2009/061106 WO2010045624A1 (en) 2008-10-16 2009-10-16 Inhibitors of mitosis for increasing apoptosis in therapy

Publications (1)

Publication Number Publication Date
SMT201600073B true SMT201600073B (it) 2016-04-29

Family

ID=41508147

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600073T SMT201600073B (it) 2008-10-16 2016-03-14 Inibitori della mitosi per aumentare l'apoptosi in terapia

Country Status (19)

Country Link
EP (1) EP2349259B1 (it)
JP (2) JP5749170B2 (it)
CN (2) CN104958292B (it)
AU (1) AU2009305588B2 (it)
BR (1) BRPI0920878A2 (it)
CA (1) CA2741069C (it)
CY (1) CY1117281T1 (it)
DK (1) DK2349259T3 (it)
ES (1) ES2565778T3 (it)
HR (1) HRP20160267T1 (it)
HU (1) HUE027170T2 (it)
IL (1) IL212413A (it)
PL (1) PL2349259T3 (it)
RS (1) RS54647B1 (it)
RU (1) RU2519145C2 (it)
SI (1) SI2349259T1 (it)
SM (1) SMT201600073B (it)
UA (1) UA106214C2 (it)
WO (1) WO2010045624A1 (it)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104958292B (zh) * 2008-10-16 2018-10-16 阵列生物制药公司 用于在治疗中增加凋亡的有丝分裂抑制剂
TWI427054B (zh) * 2012-01-20 2014-02-21 Nat Univ Chung Hsing A pharmaceutical composition for inhibiting and treating a lung tumor and inhibiting an inflammatory reaction and a method for preparing the same
CN104869995A (zh) 2012-08-13 2015-08-26 阵列生物制药公司 用于治疗低aag患者的癌症的arry-520
EP3030236A1 (en) 2013-08-08 2016-06-15 Array Biopharma, Inc. Filanesib combined with pomalidomide displays enhanced anti-tumor activity
EP3254104B1 (en) * 2015-02-04 2021-08-25 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
JP7340240B2 (ja) * 2019-08-26 2023-09-07 学校法人関西医科大学 細胞又は組織にアポトーシスを誘導する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20050901A (sr) * 2003-06-05 2007-12-31 Zentaris Gmbh., Derivati indola sa efektom na apoptozu
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
CN104958292B (zh) * 2008-10-16 2018-10-16 阵列生物制药公司 用于在治疗中增加凋亡的有丝分裂抑制剂

Also Published As

Publication number Publication date
HUE027170T2 (hu) 2016-10-28
CA2741069A1 (en) 2010-04-22
UA106214C2 (ru) 2014-08-11
JP2014144979A (ja) 2014-08-14
CY1117281T1 (el) 2017-04-26
AU2009305588A1 (en) 2010-04-22
SI2349259T1 (sl) 2016-03-31
RU2519145C2 (ru) 2014-06-10
ES2565778T3 (es) 2016-04-06
PL2349259T3 (pl) 2016-07-29
IL212413A (en) 2015-08-31
EP2349259A1 (en) 2011-08-03
WO2010045624A1 (en) 2010-04-22
BRPI0920878A2 (pt) 2015-12-22
CN102256603A (zh) 2011-11-23
JP5749170B2 (ja) 2015-07-15
CN104958292A (zh) 2015-10-07
RS54647B1 (sr) 2016-08-31
RU2011119427A (ru) 2012-11-27
AU2009305588B2 (en) 2015-08-13
CA2741069C (en) 2017-08-22
HK1154813A1 (zh) 2012-05-04
DK2349259T3 (en) 2016-02-29
JP2012505924A (ja) 2012-03-08
CN104958292B (zh) 2018-10-16
IL212413A0 (en) 2011-06-30
HRP20160267T1 (hr) 2016-04-08
CN102256603B (zh) 2015-06-03
EP2349259B1 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
SMT201700037B (it) Nuovi inibitori pirrolici della s-nitrosoglutatione riduttasi come agenti terapeutici
SMT201400106B (it) Inibitori di met per incrementare l'efficacia della radioterapia
DK3130923T3 (da) Terapeutiske fremgangsmåder i forbindelse med cancerstamceller
BR112012001325A2 (pt) tratamento de distúrbios do fígado com inibidaores de pi3k
RU2557654C3 (ru) Терапевтические агенты для снижения уровней паратиреоидного гормона
DK2379600T4 (da) Antistoffer mod tissue factor pathway inhibitor
SMT201500176B (it) Composizioni e metodi per inibire l'espressione ditranstiretina
SMT201600033B (it) COMPOSIZIONI E METODI RELATIVI A VARIANTI DELLA PROTEINA A (SpA)
PT2496691T (pt) Composições de nucleases terapêuticas e métodos
HRP20160551T8 (hr) Kombinirana terapija s pripravcima nanočestica taksana i hedgehog inhibitora
BRPI1014775A2 (pt) tratamento ex vivo de distúrbios imunológicos com inibidores de pkc-teta
EP2318040A4 (en) THERAPY TREATED ON CANCER STAMPS
DK2288727T3 (da) Prædiktorer for patientrespons på behandling med EGF-receptorinhibitorer
HRP20181608T1 (hr) Korištenje inhibitora pde7 u liječenju bolesti kretanja
PL3045474T3 (pl) Środki terapeutyczne do leczenia chorób związanych z niepożądaną proliferacją komórek
HRP20190216T1 (hr) Uporaba fluopirama za suzbijanje sclerotinia ssp
SMT201400057B (it) Composizione per il trattamento della fibrosi cistica
HRP20182043T8 (hr) Upotreba anti-koneksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze
PL2435825T3 (pl) Sposoby leczenia chorób
IL245283B (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
EP2247297A4 (en) THERAPEUTIC TREATMENT OF LUNG DISEASES
EP2421506A4 (en) NANOTRANT THERAPY FOR THE TREATMENT OF INVASIVE TUMORS
LT2506840T (lt) Hipoksija sukeliančio faktoriaus inhibitorių naudojimas
DK3211005T3 (da) Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme
BRPI0921679A2 (pt) composto útil para tratar celulite